Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study
作者： Jacques Cadranel , Keunchil Park , Oscar Arrieta , Miklos Pless , Edmond Bendaly
DOI: 10.1016/J.LUNGCAN.2016.05.004
关键词:
摘要: Abstract Objectives Second-generation ALK inhibitors are recently available for + non-small cell lung cancer (NSCLC) patients previously treated with crizotinib. This study described characteristics, treatment sequencing, and outcomes among locally advanced/metastatic crizotinib-experienced NSCLC patients. Materials methods From July 2014 to June 2015, a retrospective patient chart review was conducted physicians from the US, EU, Korea, Latin America. Participating clinicians identified their who received crizotinib reported on clinical treatments, survival using pre-defined case report form. Kaplan-Meier analyses were used describe overall (OS) clinician-defined progression-free (PFS). Results reviewed charts of 158 during period. Crizotinib most commonly in second-line setting (41% patients), though this varied across geographical regions. Roughly half (53%) discontinued further antineoplastic therapy; second-generation (44%) chemotherapy (42%) regimens frequently. Following discontinuation, median OS 8.2 months. Among did not initiate inhibitor following crizotinib, 4.9 months; those did, reached. immediately time PFS post-crizotinib initiation 3.6 Conclusion many no therapy, poor receive inhibitor. Recently may provide important options
sci-hub.se 参考文章(24)
Sven Perner, Patrick L Wagner, Francesca Demichelis, Rohit Mehra, Christopher J LaFargue, Benjamin J Moss, Stefanie Arbogast, Alex Soltermann, Walter Weder, Thomas J Giordano, David G Beer, David S Rickman, Arul M Chinnaiyan, Holger Moch, Mark A Rubin, EML4-ALK Fusion Lung Cancer: A Rare Acquired Event Neoplasia. ,vol. 10, pp. 298- 302 ,(2008) , 10.1593/NEO.07878
Annie Guérin, Medha Sasane, Jie Zhang, Alexander R. Macalalad, Philip Galebach, John Jarvis, Andrew Kageleiry, Kenneth Culver, Eric Q. Wu, Heather Wakelee, ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiology. ,vol. 39, pp. 307- 312 ,(2015) , 10.1016/J.CANEP.2015.04.005
Cesare Gridelli, Solange Peters, Assunta Sgambato, Francesca Casaluce, Alex A. Adjei, Fortunato Ciardiello, ALK inhibitors in the treatment of advanced NSCLC Cancer Treatment Reviews. ,vol. 40, pp. 300- 306 ,(2014) , 10.1016/J.CTRV.2013.07.002
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin J. Solomon, Juergen Wolf, Michael Thomas, Martin Schuler, Geoffrey Liu, Armando Santoro, Yvonne Y. Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman, Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 370, pp. 1189- 1197 ,(2014) , 10.1056/NEJMOA1311107
David S Ettinger, Douglas E Wood, Wallace Akerley, Lyudmila A Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T Cheney, Lucian R Chirieac, Thomas A D’Amico, Todd L Demmy, Thomas J Dilling, M Chris Dobelbower, Ramaswamy Govindan, Frederic W Grannis, Leora Horn, Thierry M Jahan, Ritsuko Komaki, Lee M Krug, Rudy P Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Jyoti D Patel, Katherine M Pisters, Karen Reckamp, Gregory J Riely, Eric Rohren, Steven E Schild, Theresa A Shapiro, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes, None, Non–Small Cell Lung Cancer, Version 6.2015 Journal of The National Comprehensive Cancer Network. ,vol. 13, pp. 515- 524 ,(2015) , 10.6004/JNCCN.2015.0071
Stephen G. Chun, Kevin S. Choe, Puneeth Iyengar, John S. Yordy, Robert D. Timmerman, Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biology & Therapy. ,vol. 13, pp. 1376- 1383 ,(2012) , 10.4161/CBT.22255
Jennifer M. Boland, Sibel Erdogan, George Vasmatzis, Ping Yang, Lori S. Tillmans, Michele R. Erickson Johnson, Xiaoke Wang, Lisa M. Peterson, Kevin C. Halling, Andre M. Oliveira, Marie Christine Aubry, Eunhee S. Yi, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non–small cell lung carcinomas Human Pathology. ,vol. 40, pp. 1152- 1158 ,(2009) , 10.1016/J.HUMPATH.2009.01.012
Daisy Wing-Sze Wong, Elaine Lai-Han Leung, Kimpton Kam-Ting So, Issan Yee-San Tam, Alan Dart-Loon Sihoe, Lik-Cheung Cheng, Kwok-Keung Ho, Joseph Siu-Kie Au, Lap-Ping Chung, Maria Pik Wong, , The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. ,vol. 115, pp. 1723- 1733 ,(2009) , 10.1002/CNCR.24181
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Kimie Nomura, Hironori Ninomiya, Michiyo Okui, Yukitoshi Satoh, Sakae Okumura, Ken Nakagawa, Manabu Soda, Young Lim Choi, Toshiro Niki, Hiroyuki Mano, Yuichi Ishikawa, EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers Journal of Thoracic Oncology. ,vol. 3, pp. 13- 17 ,(2008) , 10.1097/JTO.0B013E31815E8B60
Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886